UroGen Pharma Ltd.
DE ˙ DB ˙ IL0011407140
23,18 EUR ↑0,82 (3,67%)
2026-06-05
PREȚUL ACȚIUNILOR
SecurityDE:UR8 / UroGen Pharma Ltd.
InstitutionState Street Corp
Latest Disclosed Ownership874,176 shares
Latest Disclosed Value $ 15,717,684
State Street Corp reports 8.27% increase in ownership of UR8 / UroGen Pharma Ltd.

On May 15, 2026 - State Street Corp filed a 13F-HR form disclosing ownership of 874,176 shares of UroGen Pharma Ltd. (DE:UR8) valued at $12,762,970 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 807,421 shares of UroGen Pharma Ltd.. This represents a change in shares of 8.27% during the quarter. The current value of the position is $20,263,400 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F UROGEN PHARMA COM M96088105 874,176 66,755 8.27 15,718 -16.88 0.0005
2026-02-13 2025-12-31 13F UROGEN PHARMA COM M96088105 807,421 -12,025 -1.47 18,910 15.67 0.0006
2025-11-14 2025-09-30 13F UROGEN PHARMA COM M96088105 819,446 11,808 1.46 16,348 47.75 0.0006
2025-08-14 2025-06-30 13F UROGEN PHARMA COM M96088105 807,638 12,626 1.59 11,065 25.84 0.0004
2025-05-15 2025-03-31 13F UROGEN PHARMA COM M96088105 795,012 -13,041 -1.61 8,793 2.17 0.0004
2025-02-14 2024-12-31 13F UROGEN PHARMA COM M96088105 808,053 38,470 5.00 8,606 -11.95 0.0003
2024-11-14 2024-09-30 13F UROGEN PHARMA COM M96088105 769,583 42,907 5.90 9,774 -19.85 0.0004
2024-08-14 2024-06-30 13F UROGEN PHARMA COM M96088105 726,676 189,682 35.32 12,194 51.39 0.0005
2024-05-15 2024-03-31 13F UROGEN PHARMA COM M96088105 536,994 46,163 9.41 8,055 9.40 0.0004
2024-02-14 2023-12-31 13F UROGEN PHARMA COM M96088105 490,831 36,727 8.09 7,362 15.74 0.0004
2023-11-14 2023-09-30 13F UROGEN PHARMA COM M96088105 454,104 35,059 8.37 6,362 46.67 0.0004
2023-08-14 2023-06-30 13F UROGEN PHARMA COM M96088105 419,045 298,823 248.56 4,337 290.72 0.0002
2023-05-15 2023-03-31 13F UROGEN PHARMA COM M96088105 120,222 7,632 6.78 1,111 11.22 0.0001
2023-05-15 2022-12-31 13F/A-99 UROGEN PHARMA COM M96088105 112,590 10,008 9.76 999 17.00 0.0001
2023-05-15 2022-12-31 13F UROGEN PHARMA COM M96088105 112,590 10,008 999 0.0001
2022-11-15 2022-09-30 13F UROGEN PHARMA COM M96088105 102,582 -33,039 -24.36 853 -23.22 0.0001
2022-08-15 2022-06-30 13F UROGEN PHARMA COM M96088105 135,621 -412,620 -75.26 1,111 -76.73 0.0001
2022-05-16 2022-03-31 13F UROGEN PHARMA COM M96088105 548,241 41,886 8.27 4,775 -0.83 0.0002
2022-02-14 2021-12-31 13F UROGEN PHARMA COM M96088105 506,355 -5,371 -1.05 4,815 -44.06 0.0002
2021-11-15 2021-09-30 13F UROGEN PHARMA COM M96088105 511,726 34,468 7.22 8,607 18.10 0.0005
2021-08-16 2021-06-30 13F UROGEN PHARMA COM M96088105 477,258 35,919 8.14 7,288 -15.23 0.0004
2021-07-09 2021-03-31 13F/A-1 UROGEN PHARMA COM M96088105 441,339 928 0.21 8,597 8.33 0.0005
2021-05-17 2021-03-31 13F UROGEN PHARMA COM M96088105 441,339 928 8,597 0.0005
2021-02-16 2020-12-31 13F UROGEN PHARMA COM M96088105 440,411 26,941 6.52 7,936 -0.50 0.0005
2020-11-10 2020-09-30 13F UROGEN PHARMA COM M96088105 413,470 -11,731 -2.76 7,976 -28.18 0.0005
2020-08-14 2020-06-30 13F UROGEN PHARMA COM M96088105 425,201 29,056 7.33 11,106 57.15 0.0008
2020-06-19 2020-03-31 13F/A-1 UROGEN PHARMA COM M96088105 396,145 -15,549 -3.78 7,067 -48.56 0.0006
2020-05-11 2020-03-31 13F UROGEN PHARMA COM M96088105 396,145 -15,549 7,067 620.6249
2020-02-06 2019-12-31 13F UROGEN PHARMA COM M96088105 411,694 23,865 6.15 13,738 48.65 0.0009
2019-11-14 2019-09-30 13F UROGEN PHARMA COM M96088105 387,829 22,687 6.21 9,242 -29.57 0.0007
2019-08-14 2019-06-30 13F UROGEN PHARMA COM M96088105 365,142 288,275 375.03 13,123 362.24 0.0010
2019-05-15 2019-03-31 13F UROGEN PHARMA COM M96088105 76,867 37,642 95.96 2,839 68.09 0.0002
2019-02-12 2018-12-31 13F UROGEN PHARMA COM M96088105 39,225 2,665 7.29 1,689 -2.20 0.0002
2018-11-09 2018-09-30 13F UROGEN PHARMA Common Stock M96088105 36,560 5,400 17.33 1,727 11.28 0.0001
2018-08-14 2018-06-30 13F UROGEN PHARMA Common Stock M96088105 31,160 31,160 1,552 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.